Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Live Free or Die? New Hampshire Court Lifts Ban on Physician Prescribing Data

This article was originally published in RPM Report

Executive Summary

Pharmaceutical sales and marketing teams will have a much easier time selling their products in one US state-and may have avoided major restrictions in others across the country-after a New Hampshire law banning the use of physician prescribing data for commercial use was struck down in state court. But drug marketers will need to continue to keep an eye on a less restrictive program sponsored by the American Medical Association.

You may also be interested in...

Flying Blind: Learning to Live Without Physician Prescribing Data

Physicians aren't happy about the prescribing information companies use to help develop sales and marketing activities, and they're doing something about it. Policies adopted by medical professionals--and legislation moving at the state level--threaten to cut off marketers' access to information about who prescribes their products. Pharma companies better prepare to adapt to new ways of tracking sales.

US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’

Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.

Drug-Drug Interactions: Future FDA Guidance Will Focus On Specific Modalities; Patient Website To Come

US FDA took ‘broadest’ approach possible with initial guidance on drug-drug interactions; additional documents will dive into issues specific to different therapeutic areas. But PK/PD modeling and AI alternatives will have to wait.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts